TELA Bio Highlights Results from BRAVO and ReBAR Studies on the Benefits of OviTex® Reinforced Tissue Matrix in Hernia Repairs; Data to Be Presented at 2022 American Hernia Society (AHS) Meeting
24-Month BRAVO study results showed a 2.6% recurrence rate in diverse clinical scenarios
Robotic Reinforced Biologic Augmented Repair (ReBAR) study showed a 1.9% recurrence rate at two-year mark
MALVERN, Pa., Aug. 04, 2022 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative technologies that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy, today announced that two studies examining clinical outcomes with use of its OviTex Reinforced Tissue Matrix will be presented at the 2022 American Hernia Society (AHS) Meeting.
The conference, taking place from September 14-16, 2022, in Charlotte, North Carolina, will highlight the outcomes of two studies that underscore the efficacy of OviTex.
24-Month results of the BRAVO Study: A prospective, multi-center study evaluating the clinical outcomes of ventral hernias treated with OviTex 1S Permanent Reinforced Tissue Matrix
These BRAVO 24-Month results follow the publication of the BRAVO 12-Month study, released in November 2021 in the Journal of Clinical Medicine.
Robotic Reinforced Biologic Augmented Repair (ReBAR) of Over 150 Inguinal Hernias: 2-Year Outcomes
“We are proud to share these positive clinical results for both our BRAVO patient population and those who underwent a ReBAR repair. We believe this research demonstrates that we’re succeeding in our mission to provide an effective portfolio of tissue reinforcement solutions while minimizing the permanent synthetic polymer footprint,” stated Antony Koblish, President and CEO of TELA Bio. "Today’s patients are eager for a repair solution that is more natural and contains less permanent foreign bodies. These results show that OviTex not only meets these criteria but also contributes to increasing patient quality of life.”
About TELA Bio, Inc.
The statements made or results achieved by TELA Bio customers described herein were achieved in their specific setting. Due to variations in clinical experience and technique, there is no guarantee that these results are typical. A surgeon must use his or her own clinical judgment when deciding which products are appropriate for treatment of a particular patient. Always refer to the package insert, product label, and/or instructions for use before using any TELA Bio product. Products may not be available in all markets because product availability is subject to the regulatory and/or medical practices in individual markets.
Caution Regarding Forward-Looking Statements